Amphenol Corp
Electrical Equipment
Amphenol Corp (APH) Stock News
The latest APH headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
GRAPHIC PACKAGING DEADLINE MONDAY JULY 6th: Bragar Eagel & Squire, P.C. Reminds Graphic Packaging Holding Company Investors They Have Until July 6th to Contact the Firm Seeking Lead Plaintiff Role
A class action lawsuit has been filed against Graphic Packaging Holding Company for allegedly making false and misleading statements regarding inventory management issues, reduced demand, increased costs, and overstating business strength. The lawsuit covers securities purchased between February 4, 2025 and February 2, 2026. Investors have until July 6, 2026 to apply as lead plaintiff.
- GlobeNewswire Inc.·
GRAPHIC PACKAGING DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Graphic Packaging Holding Company Investors They Have Until July 6th to Contact the Firm Seeking Lead Plaintiff Role
A class action lawsuit has been filed against Graphic Packaging Holding Company for allegedly making false and misleading statements regarding inventory management issues, reduced demand, increased costs, and unreliable financial guidance for FY 2025. Investors who purchased securities between February 4, 2025 and February 2, 2026 have until July 6, 2026 to apply as lead plaintiff.
- GlobeNewswire Inc.·
GRAPHIC PACKAGING ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Graphic Packaging Holding Company and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against Graphic Packaging Holding Company for allegedly making false and misleading statements regarding inventory management issues, reduced demand, increased costs, and unreliable financial guidance for FY 2025. Investors who purchased GPK securities between February 4, 2025 and February 2, 2026 can seek lead plaintiff status by July 6, 2026.
- GlobeNewswire Inc.·Neutral
SAPHNELO Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
SAPHNELO (Anifrolumab), a first-in-class type I interferon receptor blockade monoclonal antibody for moderate-to-severe SLE, is projected to see strong market growth through 2034 across major markets. The drug generated approximately $483 million in the first nine months of 2025 and has been approved in over 70 countries. However, the FDA issued a Complete Response Letter in February 2026 for the subcutaneous formulation, which AstraZeneca is working to address.